Great time to buy Pfizer

Drug makers should see strong gains over the next few years, particularly due to the aging population. However, they still face challenges. For example, they must continually invest large sums to develop new drugs as patents expire on older ones. New drugs can also take… Read More

PFIZER INC. $23 – New York symbol PFE

PFIZER INC. $23 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 7.5 billion; Market cap: $172.5 billion; Price-to-sales ratio: 2.5; Dividend yield: 3.8%; TSINetwork Rating: Above Average; www.pfizer.com) is the world’s largest pharmaceutical drug maker. Its top-selling brands include Lipitor (for… Read More

Stanley has room to grow

Expanding through acquisitions is riskier than internal growth. However, some companies have a strong history of buying and integrating new businesses, and making them more profitable. A top example is Stanley, which has spent over $3.0 billion on acquisitions since 2002, not including last year’s… Read More

Hold Verigy for a higher bid

VERIGY LTD. $13.49 (Nasdaq symbol VRGY; SI Rating: Extra Risk) (1-800-447-8378; www.verigy.com; Shs. outstanding: 60 million; Market cap: $807.7 million; No dividends paid) is now the subject of a $12.15-a-share takeover offer from Japan-based Advantest Corp. Advantest is the world’s largest maker of systems that… Read More